Provectus Biopharmaceuticals Rose Bengal Immunotherapy Q2 2024

Provectus Biopharmaceuticals presents its small molecule immunotherapy program focused on Rose Bengal Sodium (RBS), a photodynamic therapy agent under development. The Q2 2024 investor presentation outlines the company's clinical strategy and potential applications for this novel therapeutic candidate.